Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 2/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664062 | 0.80 | CYP1A2 (0.56) | CSNK2A1MAPT | |
| SCHEMBL1723735 | 0.80 | CNR2 (0.45) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL29818135 | 0.73 | NPC1 (0.63) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL180650 | 0.72 | DGAT1 (0.69) | CSNK2A1TBK1CSNK2A2CSNK2B | |
| SCHEMBL1448287 | 0.72 | DGAT1 (0.50) | HDAC3HDAC1HDAC2HDAC6CSNK2A1 | |
| SCHEMBL16546762 | 0.72 | DGAT1 (0.64) | — | |
| SCHEMBL13664059 | 0.72 | DGAT1 (0.64) | — | |
| SCHEMBL180787 | 0.72 | DGAT1 (0.64) | — | |
| SCHEMBL180699 | 0.72 | DGAT1 (0.64) | PIK3CG | |
| SCHEMBL18560419 | 0.71 | SLC22A12 (0.44) | HDAC1HDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101415683-B | Novel compounds | NOVARTIS AG | 2013-07-17 | — | — | CN | claimed |
| EP-2404905-A1 | New compounds | Novartis AG (CH) | 2012-01-11 | — | — | EP | claimed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | claimed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | claimed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8835451-B2 | Compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| CN-103288721-A | (4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-n-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof | NOVARTIS AG | 2013-09-11 | — | — | CN | disclosed |
| CN-101415683-B | Novel compounds | NOVARTIS AG | 2013-07-17 | — | — | CN | disclosed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| CN-101600437-A | method for preventing or treating myocardial ischemia | NOVARTIS AG (CH) | 2009-12-09 | — | — | CN | disclosed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | disclosed |
| EP-2101783-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | Novartis Ag (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | HDAC3 1069/4885HDAC1 683/4885HDAC2 967/4885 |
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | HDAC3 1069/4885HDAC1 683/4885HDAC2 967/4885 |
| US-20130018054-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | HDAC3 973/4885HDAC1 615/4885HDAC2 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.